NF2 and neoplasm: Genetic studies on PM reported a low prevalence of oncogene driver mutations and low tumor mutational burden, and the vast majority of recurrent mutations predominantly result in loss-of-function of tumor suppressors, including BAP1, TP53, CDKN2A, NF2, and LATS2 [12, 13].